文献速递胸部肿瘤

克唑替尼治疗东亚ROS1阳性晚期非小细胞肺癌的II期研究

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2018-03-29

该II期开放标签单臂研究纳入127例东亚ROS1阳性晚期非小细胞肺癌患者,口服克唑替尼250mg每日两次。独立影像学评估的客观缓解率为71.7%(95%CI 63.0%-79.3%),中位缓解持续时间19.7个月,中位无进展生存期15.9个月,安全性可耐受。

要点

  • 克唑替尼在东亚ROS1阳性晚期NSCLC中客观缓解率达71.7%,疗效不受既往治疗线数影响。
  • 中位缓解持续时间19.7个月,中位无进展生存期15.9个月,显示持久获益。
  • 安全性特征与既往报告一致,未发现新的安全信号。

核心结论

  • 克唑替尼在东亚ROS1阳性晚期NSCLC患者中显示出有临床意义的获益和持久的缓解。
  • 克唑替尼总体耐受良好,安全性特征与既往报告一致。

研究设计与样本

  • II期、开放标签、单臂试验,纳入东亚ROS1阳性晚期NSCLC患者,接受≤3线既往系统治疗。
  • ROS1阳性通过验证的AmoyDx检测在三个区域实验室评估。
  • 克唑替尼口服起始剂量250mg每日两次,持续至RECIST 1.1版定义的进展(独立影像学评估)、不可接受毒性或撤回知情同意。
  • 主要终点为独立影像学评估的客观缓解率,疗效和安全性分析纳入127例患者。

主要发现

  • 独立影像学评估的客观缓解率为71.7%(95%CI 63.0%-79.3%),包括17例完全缓解和74例部分缓解。
  • 客观缓解率与既往治疗线数无关。
  • 中位缓解持续时间为19.7个月(95%CI 14.1个月-未达到)。
  • 独立影像学评估的中位无进展生存期为15.9个月(95%CI 12.9-24.0个月)。
  • 未报告克唑替尼相关的新安全信号。

临床怎么用

  • 对于ROS1阳性晚期NSCLC的东亚患者,克唑替尼250mg每日两次可作为有效且耐受良好的治疗选择。

局限性

  • 单臂设计,无对照组的直接比较。
  • 样本量有限(127例),随访时间受数据截止影响。
  • 仅纳入东亚人群,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Approximately 1% to 2% of non-small-cell lung cancers (NSCLCs) harbor a c-ros oncogene 1 ( ROS1) rearrangement. Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), ROS1, and MET, has shown marked antitumor activity in a small expansion cohort of patients with ROS1-positive advanced NSCLC from an ongoing phase I study. We assessed the efficacy and safety of crizotinib in the largest cohort of patients with ROS1-positive advanced NSCLC. Patients and Methods This phase II, open-label, single-arm trial enrolled East Asian patients with ROS1-positive (assessed through validated AmoyDx assay [Amoy Diagnostics, Xiamen, China] at three regional laboratories) advanced NSCLC who had received three or fewer lines of prior systemic therapies. Patients were to receive oral crizotinib at a starting dose of 250 mg twice daily and continued treatment until Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1-defined progression (by independent radiology review [IRR]), unacceptable toxicity, or withdrawal of consent. The primary end point was objective response rate (ORR) by IRR. Results In the efficacy and safety analyses, 127 patients were included, with 49.6% still receiving treatment at data cutoff. ORR by IRR was 71.7% (95% CI, 63.0% to 79.3%), with 17 complete responses and 74 partial responses. ORRs were similar irrespective of the number of prior lines of therapy, and responses were durable (median duration of response, 19.7 months; 95% CI, 14.1 months to not reached). Median progression-free survival by IRR was 15.9 months (95% CI, 12.9 to 24.0 months). No new safety signals associated with crizotinib were reported. Conclusion This study demonstrated clinically meaningful benefit and durable responses with crizotinib in East Asian patients with ROS1-positive advanced NSCLC. Crizotinib was generally well tolerated, with a safety profile consistent with previous reports.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wu YL, Yang JC, Kim DW, et al. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018. PMID: 29596029. doi:10.1200/JCO.2017.75.5587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。